Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIP5K7)

• Drug Name: N,N-Dimethyl-3,3-diphenylpropan-1-amine Drug Info
• Synonyms: 3,3-Diphenyl-N-dimethylpropylamine; 4646-55-3; Oprea1_032403; N,N-Dimethyl-3,3-diphenylpropan-1-amine; AC1Q3WP9; AC1L45WF; diphenylalkylamine (DPA), 5c; SCHEMBL1802493; 3,3-Diphenylpropyldimethylamine; CHEMBL610739; CTK1C5217; BDBM35934; DTXSID90196845; (3,3-diphenylpropyl)dimethylamine; ZINC1679452; 3,3-diphenyl-N,N-dimethylpropylamine; AKOS016035475; Benzenepropanamine, N,N-dimethyl-gamma-phenyl-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 151221
  CAS Number: CAS 4646-55-3
  TTD Drug ID: DMIP5K7

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[2]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[3]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[4]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[5]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[6]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[7]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[8]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[9]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[10]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[11]

Drug(s) Targeting Histamine H1 receptor (H1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[12]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[13]
Azelastine	DMXTMBJ	Allergic conjunctivitis	9A60.02	Approved	[14]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[15]
Cinnarizine	DM7U5QJ	Meniere disease	AB31.0	Approved	[16]
Diphenhydramine	DMKQTBA	Hyperemesis gravidarum		Approved	[14]
Doxepin	DMPI98T	Anxiety		Approved	[17]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[14]
Epinastine	DMX0K3Q	Allergic conjunctivitis	9A60.02	Approved	[18]
Desloratadine	DM56YN7	Allergic rhinitis	CA08.0	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Inhibitor	[1]
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Inhibitor	[1]

References

• [1] Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504.
• [2] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [3] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [4] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [5] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [6] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [7] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [9] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [10] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [11] Clinical pipeline report, company report or official report of Lundbeck.
• [12] Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
• [13] Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
• [14] Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
• [15] Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
• [16] Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
• [17] Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
• [18] Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
• [19] Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.